Report
Rune Majlund Dahl
EUR 436.87 For Business Accounts Only

Coloplast (Buy, TP: DKK745.00) - Margin uplift in Q3e

We expect Coloplast to deliver 8.3% organic growth in Q3 (results due at c12:00 CET on 8 August) driven by continued strong momentum in Emerging Markets and the US. We further expect unchanged full-year guidance but believe it can reach the high end for organic revenue growth and EBIT margin guidance as we forecast a significant margin improvement in Q3 and Q4. Coloplast is due to host a CMD on 18 September, where we expect focus to be on new innovative products. We keep our BUY, with a new target price of DKK745 (645).
Underlying
Coloplast A/S Class B

Coloplast is a supplier of intimate healthcare products and services. Co. develops and markets products that support people with diseases of a private nature. Co. operates in three business areas: Ostomy care, products for people whose intestinal outlet has been rerouted through the abdominal wall; Urology and continence care products, for people suffering from diseases of the kidneys, the urinary system and the male reproductive system; Dressings, for the treatment of chronic wounds and skin care products for prevention and treatment. Co. markets and sells its products and services globally. Co. supplies products to hospitals, institutions as well as wholesalers and retailers.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Rune Majlund Dahl

Other Reports on these Companies
Other Reports from DnB Markets
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner

ResearchPool Subscriptions

Get the most out of your insights

Get in touch